Novakand Pharma AB (publ) (LARK) — Capital Reinvestment Ratio
Novakand Pharma AB (publ) (LARK) has a Capital Reinvestment Ratio of 0.01x as of December 2021, meaning it reinvests 0% of its operating cash flow (Skr22.11 Million) in capital expenditures (Skr147.73K). See how much free cash does Novakand Pharma AB (publ) generate to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Novakand Pharma AB (publ) Capital Reinvestment Ratio (2018–2021)
This chart tracks Novakand Pharma AB (publ)'s Capital Reinvestment Ratio across 2 annual periods. See financial flexibility index of Novakand Pharma AB (publ) to measure the company's free cash flow as a share of total liabilities.
Annual Capital Reinvestment Ratio for Novakand Pharma AB (publ) (2018–2021)
Year-by-year Capital Reinvestment Ratio for Novakand Pharma AB (publ) from 2018 to 2021. For the full cash flow conversion analysis, see Novakand Pharma AB (publ) cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (SEK) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.01x | Skr22.11 Million | Skr147.73K | ▼ -99.6% |
| 2018 | 1.89x | Skr227.60K | Skr430.20K | — |